Zolpidem
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Zolpidem: Benign paroxysmal torticollis of infancy
One-Sentence Summary
Zolpidem is a sedative-hypnotic originally used to treat insomnia. No clinical trials are registered for this prediction, but 20 publications (reviews, guidelines, network meta-analyses and one Phase 3 RCT with zolpidem ER as comparator) discuss the drug in this setting.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Benign paroxysmal torticollis of infancy |
| TxGNN Prediction Score | 0.9926 |
| Evidence Level | L5 (as assigned in the data compiled for this report; see note below) |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Note on evidence level: The L1 grade rests on a network meta-analysis, a clinical practice guideline and a Phase 3 trial in which zolpidem ER served only as an active comparator. No completed Phase 3 trials with zolpidem as the primary study drug are registered for this prediction. Because the indication is already approved, the grade reflects well-established use rather than new-indication evidence.
Why is This Prediction Reasonable?
Zolpidem is a positive allosteric modulator of the GABA-A receptor with preferential affinity for the alpha-1 subunit, which mediates sedative-hypnotic effects. Detailed mechanism-of-action data was not included in the data compiled for this report, but this mechanism is well established in the literature.
“Difficulty initiating and maintaining sleep” is essentially a synonym for insomnia, the drug’s original indication. The prediction is therefore best read as a re-labeling of the approved use, not as true repurposing.
Two other predictions were also generated, but they lack support:
- Benign paroxysmal torticollis of infancy (score 0.9926): no identifiable mechanistic link, no trials or literature, and sedative-hypnotics raise safety concerns in infants. Decision: Hold.
- Agoraphobia (score 0.9925): the rationale is weak, because zolpidem’s alpha-1 selectivity gives it minimal anxiolytic activity. Guideline-preferred treatments are SSRIs/SNRIs and CBT, and the risks of dependence, complex sleep behaviors and next-day impairment argue against use. No trials or literature support it. Decision: Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35843245 | 2022 | Network meta-analysis | Lancet | Compared the effectiveness of drug treatments for acute and long-term management of insomnia in adults |
| 27998379 | 2017 | Clinical practice guideline | J Clin Sleep Med | AASM guideline on drug treatment of chronic insomnia in adults, covering individual drugs |
| 31880796 | 2019 | RCT (Phase 3) | JAMA Netw Open | Lemborexant vs placebo and zolpidem ER in older adults with insomnia; zolpidem ER was the active comparator |
| 34121443 | 2021 | Network meta-analysis | J Manag Care Spec Pharm | Efficacy and safety of lemborexant compared with other insomnia treatments |
| 39923608 | 2025 | Guideline (expert consensus) | Sleep Med | European guidance on switching or deprescribing hypnotics for chronic insomnia; lists Z-drugs including zolpidem |
| 41187937 | 2025 | Guideline | Arq Neuropsiquiatr | Brazilian guideline on Z-drug abuse and dependence; use recommended for no more than four weeks |
| 29487083 | 2018 | Review | Pharmacol Rev | Z-drugs have a strong evidence base but cause cognitive impairment, tolerance, rebound insomnia, falls, abuse and dependence |
| 30058034 | 2018 | Review | Drugs Aging | Pharmacological management of insomnia in the elderly |
| 27751669 | 2016 | Review | Clin Ther | Safety and efficacy of sleep medicines in older adults |
| 22424586 | 2012 | Review | Expert Opin Pharmacother | Zolpidem is a benzodiazepine-receptor agonist and the most widely prescribed hypnotic in the US |
India Market Information
The data compiled for this report contains no approved indication text for these licences. Of the 20 valid single-ingredient registrations, the main ones are:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 251751 | Zolit 10mg Tablet | Strip of 10 tablets | Not stated |
| 63322 | Dactive 12.5mg Tablet | Strip of 7 tablets | Not stated |
| 101218 | Goodnoct 6.25mg Tablet XR | Strip of 10 XR tablets | Not stated |
| 249782 | Zedem 12.5mg Tablet ER | Strip of 10 ER tablets | Not stated |
| 64429 | Dactive 10mg Tablet | Strip of 10 tablets | Not stated |
All forms are oral (immediate-release, extended-release and controlled-release tablets).
Safety Considerations
- Contraindications flagged in the knowledge graph (drug-disease edges, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, liver disease, gallbladder disease, obstructive sleep apnea syndrome, sleep apnea syndrome, congenital central hypoventilation syndrome, amnestic disorder, retrograde amnesia, substance-related disorder, substance abuse/dependence, and attention deficit hyperactivity disorder (including the inattentive type).
- Drug Interactions: 274 interactions were identified. Major interactions include morphine and liposomal morphine (additive central nervous system and respiratory depression). Moderate interactions include bupropion, aprepitant, dexamethasone, cimetidine, clarithromycin, dronabinol, nabilone, metoclopramide, miconazole, clotrimazole, glycerol phenylbutyrate, opium, sibutramine and troglitazone.
- Literature-reported concerns: cognitive impairment, tolerance, rebound insomnia on discontinuation, falls, car accidents, abuse and dependence; particular caution in older adults.
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails (for sleep disorder, initiating and maintaining sleep). Hold for benign paroxysmal torticollis of infancy and agoraphobia.
Rationale: The first prediction is effectively the approved insomnia indication, supported by guidelines and meta-analyses, so it is not a new repurposing opportunity. The other two predictions have no clinical or literature support and carry safety concerns.
To proceed, the following is needed:
- Package insert warnings and contraindications from Indian labelling. This is a blocking gap for safety screening.
- Detailed mechanism of action data from DrugBank.
- Confirmation of approved indication wording on the Indian licences.
- A decision on whether the first prediction is worth pursuing, since it adds no new indication.
- Safety guardrails for older adults, patients with sleep apnea or liver disease, and those at risk of dependence, and attention to co-prescribed opioids.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.